ORIC Pharmaceuticals Q4 2021 Earnings Call Summary

1Key Financial Results and Metrics

Q4 2021 Operating Expenses: $22.8 million, resulting in a net loss of $22.8 million.

Full Year 2021 Operating Expenses: $78.9 million, leading to a net loss of $78.7 million.

Net Cash Used in Operating Activities: Approximately $60 million for the year.

Cash and Investments: Ended 2021 with $280.4 million, extending cash runway into the second half of 2024 due to the discontinuation of ORIC-101.

2Strategic Updates and Business Highlights

Discontinuation of ORIC-101: ORIC-101, a glucocorticoid receptor (GR) inhibitor, will not proceed further due to insufficient efficacy signals in clinical trials for both prostate cancer and solid tumors.

Pipeline Development: ORIC filed three INDs for new programs:

ORIC-533: Targeting multiple myeloma.

ORIC-114: Targeting EGFR/HER2 cancers.

ORIC-944: Targeting prostate cancer.

Initial Data Expectations: Data from these programs is anticipated in the first half of 2023.

New Discovery Programs: Advancements in lead optimization, including a first-in-class PLK4 program targeting breast cancer.

3Forward Guidance and Outlook

Cash Runway: Extended to the second half of 2024, supporting ongoing clinical trials and operational needs.

Data Updates: Initial Phase 1 data from ORIC-533, ORIC-114, and ORIC-944 expected in the first half of 2023.

4Bad News, Challenges, or Points of Concern

Discontinuation of ORIC-101: The decision reflects a significant setback, as the trials did not meet efficacy benchmarks, highlighting challenges in overcoming resistance mechanisms in cancer treatment.

Efficacy Concerns: The trials revealed that despite achieving target engagement, clinical benefits were not observed, raising questions about the GR pathway's relevance in the studied populations.

Tumor Heterogeneity: Observations of tumor heterogeneity and redundancy in resistance mechanisms may complicate future development efforts.

5Notable Q&A Insights

Comparison with Competitors: Questions arose regarding the differences between ORIC-101's results and those of Corcept's studies, emphasizing the distinct patient populations and treatment regimens.

Learnings from Trials: Insights on tumor heterogeneity indicated that resistance mechanisms could evolve during treatment, complicating the effectiveness of GR inhibition.

Future Strategies: The company plans to explore combination therapies for ORIC-533 in myeloma and is open to partnerships for further development.

PLK4 Program: Anticipated to be a first-in-class opportunity with a focus on breast cancer, with further details expected at an upcoming conference. Overall, while ORIC faced significant challenges with the discontinuation of ORIC-101, the company maintains a robust pipeline and strategic focus on addressing high unmet needs in oncology.